Previous study has demonstrated that rolipram was an effective PDE4B inhibitor, which exerted important tumor suppressive effects by inhibiting the PDE4B/mTOR/Myc axis in colorectal cancer (Kim et al., 2019). Here, MYC is linked to neoplasm.